Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 6/20 | 0.70 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.53 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.53 |
| ▸ | HTR3A | P46098 | 4/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.39 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.39 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2638541 | 0.89 | CHRNA7 (0.78) | CHRNA7CHRNB4CHRNA3HTR3AKCNH2 | |
| SCHEMBL1753505 | 0.89 | CHRNA7 (0.78) | CHRNA7CHRNB4CHRNA3HTR3AKCNH2 | |
| SCHEMBL3646588 | 0.83 | CHRNA7 (0.70) | CHRNA7CHRNB4CHRNA3HTR3AKCNH2 | |
| SCHEMBL3646587 | 0.83 | CHRNA7 (0.70) | CHRNA7CHRNB4CHRNA3HTR3AKCNH2 | |
| SCHEMBL3650799 | 0.83 | CHRNA7 (0.70) | CHRNA7CHRNB4CHRNA3HTR3AKCNH2 | |
| SCHEMBL3650804 | 0.83 | CHRNA7 (0.70) | CHRNA7CHRNB4CHRNA3HTR3AKCNH2 | |
| SCHEMBL1689175 | 0.82 | CHRNA7 (1.00) | CHRNA7CHRNB4CHRNA3HTR3AKCNH2 | |
| SCHEMBL18016318 | 0.82 | CHRNA7 (1.00) | CHRNA7CHRNB4CHRNA3HTR3AKCNH2 | |
| SCHEMBL3031137 | 0.81 | CHRNA7 (0.78) | CHRNA7CHRNB4CHRNA3HTR3AKCNH2 | |
| SCHEMBL1689084 | 0.81 | CHRNA7 (0.78) | CHRNA7CHRNB4CHRNA3HTR3AKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100280015-A1 | NOVAL 1,4-DIAZA-BICLO[3.2.2]NONYL OXADIAZOLYL DERIVATIVES USEFUL AS NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | NEUROSEARCH A/S (DK) | 2010-11-04 | — | — | US | claimed |
| EP-2190847-A1 | NOVEL 1,4-DIAZA-BICYCLO[3.2.2]NONYL OXADIAZOLYL DERIVATIVES USEFUL AS NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | NEUROSEARCH A/S (DK) | 2010-06-02 | — | — | EP | claimed |
| WO-2009024516-A1 | NOVEL 1,4-DIAZA-BICYCLO[3.2.2]NONYL OXADIAZOLYL DERIVATIVES USEFUL AS NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | NEUROSEARCH A/S (DK) | 2009-02-26 | — | — | WO | claimed |
| US-20100280015-A1 | NOVAL 1,4-DIAZA-BICLO[3.2.2]NONYL OXADIAZOLYL DERIVATIVES USEFUL AS NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | NEUROSEARCH A/S (DK) | 2010-11-04 | — | — | US | disclosed |
| EP-2190847-A1 | NOVEL 1,4-DIAZA-BICYCLO[3.2.2]NONYL OXADIAZOLYL DERIVATIVES USEFUL AS NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | NEUROSEARCH A/S (DK) | 2010-06-02 | — | — | EP | disclosed |
| WO-2009024516-A1 | NOVEL 1,4-DIAZA-BICYCLO[3.2.2]NONYL OXADIAZOLYL DERIVATIVES USEFUL AS NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | NEUROSEARCH A/S (DK) | 2009-02-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100280015-A1 | NOVAL 1,4-DIAZA-BICLO[3.2.2]NONYL OXADIAZOLYL DERIVATIVES USEFUL AS NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | CHRNA6, CHRNA5, CHRNA3 | CHRNA7 4/4885CHRNB4 8/4885CHRNA3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.